McARDLE LABORATORY 
FOR CANCER RESEARCH 
DEPARTMENT Of ONCOLOGY 
MEDICAL SCHOOL, UNIVERSITY Of WISCONSIN 
March 4, 1986 
Dr. William J. Cartland, Jr. 
Recombinant DNA Advisory Committee 
Building 31, Room 3B10 
National Institutes of Health 
Bethesda , MD 20205 
Dear Bill: 
I am writing with respect to a possible oversight In the Points to Consider 
for Possible Human Cene Therapy. In recent papers concerned with stem cell 
Infections of mice, there has been co-cultlvatlon of virus-producing cells 
with the stem cells followed by subsequent reimplantation of the stem cells 
Into suitable recipients. When the Points to Consider were being drawn up, it 
was thought that all Infections would be by cell-free virus stocks. Therefore, 
there is no explicit question in the Points about the possibility of contamina- 
tion by the virus-producing cells. 
This problem may be covered by present questions about contaminating 
organisms, but might be better explicitly stated. 
With best regards. 
Sincerely yours 
Howard M. Teraln 
HKT:mjm 
Recombinant DNA Research. Volume 11 
[45] 
